Reference
Institute for Clinical and Economic Review. Institute for Clinical and Economic Review Updates Value-Based Price Benchmark for Alirocumab, a PCSK9 Inhibitor for Treatment of High Cholesterol. Internet Document : 10 Mar 2018. Available from: URL: https://icer-review.org/announcements/alirocumab-prelim-evidence-update/
Rights and permissions
About this article
Cite this article
ICER updates price benchmark for PCSK9 inhibitor, alirocumab. PharmacoEcon Outcomes News 799, 4 (2018). https://doi.org/10.1007/s40274-018-4786-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-4786-5